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Autoimmune phenomenaareknown to occur in a large variety ofhuman diseases
(for review see reference 1) . Antibodies to self-components (autoantibodies) can be
directed against organ-specific or non-organ-specific target structures and can de-
velop transiently or persist chronically. Some are regarded as diagnostic markers
for certain diseases, and some are pathogenic or contribute to disease development
(reviewed in reference 2) .
Several factors, ranging from genetic susceptibility to environmental influences,
have been proposed as triggers ofautoimmune processes . There is also ample evi-
dence for an important role of various viruses in generation of autoimmunity (3,
4) . Autoantibodies to lymphocytes are common after infection with Epstein-Barr,
rubella, and measles viruses (5) . Patients infected with hepatitis B and delta (6),
influenza (7), herpes (8), and coxsackie viruses (3) often develop antibodies to host
cell- and organ-specific antigens .
Crossreaction of antibodies with epitopes shared by microbial antigens and host
self-components, termed molecular mimicry (4, 9), is one of the mechanisms that
hasbeen speculated to initiate development of autoantibodies . Polyclonal and mono-
clonal antiviral antibodies induced by immunization were frequently observed to
crossreact with host proteins (10), and some of the target antigens bearing shared
epitopes have been identified (4) . An epitope shared by amajor humanautoantigen
and a protein of a human virus, and occurrence of the corresponding antibodies
in sera of patients with chronic autoimmune diseases, has, however, not been de-
scribed so far .
To search for shared epitopes, the autoimmune response to Ul-RNA containing
small nuclear ribonucleoprotein particles [(Ul)snRNP] 1 was used as a model system .
Anti-(Ul)snRNP autoantibodies are characteristic for certain inflammatory rheu-
matic diseases (11), and a 68-kD protein (p68) of the (Ul)snRNP particle is amajor
antigenic target (12) . ThecDNA coding for p68 has been cloned (13-16), and three
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major autoantigenic domains have been identified with different fragments of the
recombinant p68 protein (17). One of these domains is located between amino acid
positions 233 and 276 (17). Subsequent studies with fusion proteins and synthetic
peptides confined this autoreactive region to the sequence NH2-PTRAETREE-
RMERKRREKIE-COOH (amino acid position 234-253, subsequently called do-
main A), and showed that it is recognized by 35% (37/103) ofanti-p68 autoimmune
sera (H. Guldner et al., unpublished data).
Here, we demonstrate that a subset ofhuman anti-p68/domain A autoantibodies
react with a p68 epitope that is present also on the matrix protein M1 of human
influenza B viruses, and that autoimmune sera recognize this shared epitope also
in the viral sequence context.
Materials and Methods
Human Autoimmune Sera, mAbs, andInfluenza Virus Strains.
￿
Sera from patients with mixed
connective tissue disease (18) and systemic lupus erythematosus (diagnosed according to the
criteria of the American Rheumatism Association; reference 19) were obtained from Dr.
H .J. Lakomek, Department of Medicine C, Endocrinology and Rheumatology, University
of Dfisseldorf, FRG, and Dr. Frederick Miller, National Institute of Arthritis and Mus-
culoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD. Reactivity to-
wards the (Ul)snRNP-specific p68 protein was determined by immunoblotting with HeLa
nuclear extracts (20) and ELISA with recombinant p68 fusion protein (16).
Anti-p68 mAbs were generous gifts from Dr. R. Luhrmann, Institut fur Molekularbiologie
and Tumorforschung, Universitat Marburg, FRG (clone H386); Dr. S. O. Hoch, The Agouron
Institute, La Jolla, CA, (clone 2.73); and Dr. D. G. Williams, The Mathilda and Terence
Kennedy Institute of Rheumatology, London, UK (clone K8.43).
Influenza strains B/Beijing/1/87 and A/Singapore/6/86 (HIN1) grown in hen eggs were
kindly provided by Dr. J. Hinz, Behring-Werke AG, Marburg, FRG.
Immunization ofMice with Domain A PeptideandFusion Protein.
￿
Sixand four female 8-wk-old
BALB/c mice were immunized with 80-100 Rg, i.p. and s.c., respectively, of peptide RI (see
Fig. 1) coupled to palmitic acid (coupling procedure as described in reference 21) or with
50-100 lug of SDS-PAGE-purified MS2 domain A fusion protein. For the first immunization,
antigens were emulsified in CFA; for the following immunizations at days 14, 28, and 42,
the same amount of antigen emulsified in IFA was used. Blood samples were taken at days
1, 22, 51, 82, 113, 144, and 176.
Competitive Inhibition ELISA with Synthetic Peptides.
￿
Peptide Rl spanning domain A (for
amino acid sequence, see Fig. 1 a) was adsorbed to Maxisorp microtiter plates (Nunc, Roskilde,
Denmark) at a concentration of 214g/well in PBS (10 mM Na2HP04, 2 mM KH2PO4, 3 mM
KCI, 170 mM NaCl, pH 7 .4) for 2 h at room temperature, and free binding sites were satu-
rated overnight with 5 % Tween-20 in PBS (TPBS). Human autoimmune sera (diluted 1/400
in TPBS) were preincubated with inhibitor peptides (0.05 pg/p,l diluted serum; for amino
acid sequences, see Fig. 1 a) for 1 h at room temperature, followed by incubation of the
serum/peptide mixture in RI peptide-coated microtiter wells for 45 min. The amount of
antibodies bound to solid-phase RI was measured with goat anti-human IgG coupled to per-
oxidase (1/4,000 in TPBS; Medac, Hamburg, FRG) and ortho-phenylenediamine as sub-
strate. Absorbance was read at 492 nm in a Titertek Multiscan photometer (FlowLaborato-
ries, Bonn, FRG).
Construction ofRecombinant Fusion Proteins.
￿
Construction ofpEx34a plasmids expressing var-
ious subfragments of the p68 protein has been described elsewhere (17).
The expression plasmid coding for part of domain A of the p68 protein (sequence NH2-
PTRAETREERMERKRRE-COOH) was obtained by insertion ofa pair ofsynthetic oligo-
nucleotides (sequence of coding strand: 5'-GATCC CCA ACT CGT GCT GAA ACC CGA
GAG GAG CGC ATG GAG AGG AAA AGA CGG GAA TGAT3') with Barn HI and Xba I
sticky ends into vector pEx34a. Single amino acid substitutions in domain A were generated
by exchange ofthe following nucleotide positions in the coding strand ofthe synthetic oligo-GULDNER ET AL.
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nucleotide (compare Fig. 2 a): 2, 28/C; 3, 33/A; 4, 40/C; 5, 44/C; 6, 50/T; 7, 51/G; 8, 54/A,
55/G, 56/C. Correct sequence and in-frame insertion was confirmed by dideoxy sequencing
using a MS2 oligonucleotide as primer (17).
Expression andPreparation ofRecombinantFusion Proteins.
￿
Transformation ofrecombinant pEx34
plasmids in Escherichia coli 2136 cells, induction of protein expression by temperature shift,
and preparation of total bacterial extracts containing phage MS2 polymerase/p68 domain
A fusion proteins were as described elsewhere (17).
Gel Electrophoresis and Immunoblotting
￿
Total bacterial extracts or influenza virus proteins
were solubilized in sample buffer containing 27o SDS and 0.1 M dithiothreitol, separated
on 20% (E. coli extracts) or 17.5% (influenza virus proteins; 10 t~g/lane) SDS-polyacrylamide
gels (22) and transferred electrophoretically to nitrocellulose paper (23). Residual protein
binding sites were blocked with 10% horse serum in TBS (10 mM Tris-HCI, pH 7.6, 150
mM NaCl) and human autoimmune sera (diluted 1/400), or affinity-purified autoantibodies
(see below) were applied in 317o horse serum/TBS. Bound antibodies were visualized with
goat anti-human IgG, either coupled to peroxidase (1/2,000) and chloronaphthol substrate
or coupled to alkaline phosphatase (1/20,000) and NBT/BLIP substrate.
For inhibition experiments with synthetic peptides, patients' sera or affinity-purified anti-
bodies were preincubated for 1 h with peptide R12 (ERKRR, see Fig. 1) or peptide R4 (REKIE)
(10 p.g peptide per ml antibody dilution) before incubation of the antibodies on nitrocellulose
blots.
Affinity Purification ofAntibodies.
￿
For affinity purification of antibodies reactive with the
shared determinant, E. coli cell extracts containing the MS2/p68 domain A fusion protein
or total influenza B virus proteins were separated by preparative SDS-PAGE, transferred
to nitrocellulose, and stained with Ponceau S. The corresponding proteins (MS2/p68 domain
A, 17 kD; M1 matrix protein, 27 kD) were cut as horizontal strips and unblocked binding
sites were saturated with 10% horse serum in TBS. Human sera (diluted 1/100) containing
anti-ERKRR autoantibodies were incubated for 3 h, and, afterwashing with TBS/0.1 % Tween-
20, antibodies were eluted by the pH shock method (24) followed by neutralization and con-
centration in Centricon microconcentrators (Amicon Corp., Danvers, MA). As control sub-
strate for affinity purification, equivalent amounts of MS2 protein without any fused p68
sequence or Ml matrix protein of influenza A virus were used, respectively.
Results
Fine Mappingofp68Domain AAutoepitopes.
￿
Precise mapping ofdomain A autoepi-
tope(s) was performed by peptide-based competitive inhibition ELISA (Fig. 1). Pep-
tide R1, spanning the entire length of domain A (Fig. 1 a), was used as solid-phase
coupled antigen to measure binding of human anti-domain A autoantibodies after
inhibition with truncated versions of RI (peptides R2-R12; Fig. 1 a). Based on the
reaction patterns of 37 domain A-positive sera tested, three groups of sera were
identified. Group I sera reacted with peptide Rl, and this reaction could not be in-
hibited by any of the shorter peptides R2-12 (e.g., serum AA), suggesting that both
the NH2- and COON-terminal amino acid residues of domain A are involved in
autoantibody binding. In contrast, reaction of group II sera with R1 was markedly
reduced upon preincubation with all peptides containing the ERKRR motif (RI,
R2, R6-12), but not with any of the peptides with truncated versions ofthe ERKRR
motif (R3-R5; e.g., serum UG). Thus, group II sera (8 of 37 domain A-positive
sera) contain autoantibodies to an epitope located within the sequence ERKRR.
The reactivity of group III sera (5 of 37 domain A-positive sera; data not shown)
was only partially reduced upon preincubation with shortened ERKRRcontaining
peptides, suggesting that they contain both group I and II autoantibodies.
AminoAcidSubstitutionswithin Domain A.
￿
To investigate ifall residues ofthe ERKRR
motif are essential for immunoreactivity, a series of MS2-p68 fusion proteins with82 2
￿
AUTOANTIBODIES RECOGNIZE A COMMON SELF/VIRUS-EPITOPE
FIGURE 1.
￿
Identification ofautoreactive epitopes
in domain A by competitive inhibition ELISA
with truncated peptides as inhibitors for
autoantibody-binding to solid-phase coupled RI
peptide. (a) Peptides used for preincubation of
human autoimmune sera (numbers correspond
to columns in b), and reaction patterns of group
I and II sera. (b) ELISA demonstrating the in-
hibitory effects of the peptides for a representa-
tive group I (patientAA withMCTD)andgroup
II serum (patient UG with SLE). Both types of
sera (diluted 1/400) showed strong binding to the
solid-phase coupled RI peptide (column O,
without inhibition), which wasdrastically reduced
upon preincubation with the homologous pep-
tide RI (column 1) . No reduction of the signal
was observed after preincubation with any oftwo
unrelated control peptides (Cl, column 14 ; and
C2, column 15) . Preincubation of the sera with
truncated peptides R2-12 (columns 2-12) allowed
classification of the sera: serumAA (group I, dotted
bars) could not be inhibited by any of the trun-
catedpeptides R2-12 . In contrast, group II serum
UG (felled bars) was inhibited by peptides con-
taining theERKRRmotif(R2andR6-12). Pep-
tides lacking the completeERKRRsequence (R3,
R4, and R5) hadno inhibitory effects on group
II autoantibodies . Changing theamino acid ly-
sine (K) of the ERKRR motif to isoleucine (I,
peptideM3) resulted in significant but, compared
with R12, less efficient inhibition ofgroup II sera
(compare columns 12 and 13) .
single amino acid exchanges in the domain A region were generated and tested by
immunoblotting withERKRRpositive sera (Fig. 2) . All examined substitutions within
theERKRRmotif abolished immunoreactivity (Fig. 2 b, lanes 4-7), whereassubsti-
tutions in the NH2- or COOH-terminal-flanking regions did not (Fig . 2 b, lanes
2, 3, and 8) . Competitive inhibition ELISA with peptide M3 (Fig. 1, column 13)
did, however, indicate that changing theamino acid lysine (K) oftheERKRR motif
to isoleucine (I) decreases but does not prevent antibody binding . These data sug-
gest that all five amino acids of theERKRR motif are important for bindingof au-
toantibodies, although the lysine residue is not essential,
Identification of a Shared ERKRR Motif on Influenza B Matrix Protein .
￿
Computer-
assisted search of the protein sequence data bank (software package of the Univer-
sity ofWisconsin Genetics Computer Group, version 5.3, 1988) revealed theERKRR
motifalso within the M1 matrix protein ofinfluenzaB viruses(B/Lee/40 and B/Sing-
apore/222/79 ; amino acid positions 73-77 : NH2-ERKRR-COOH ; references 25
and 26) . Theanalogous proteins ofinfluenzaAviruses (A/Udorn/72andA/PR/8/34 ;
references 25 and27) do nothave this motif(amino acid position 73-77 : GLQRR) .
Other viral or bacterial proteins with an ERKRR motif have not been found.
Crossreaction ofHuman Anti-ERKRR Autoantibodies with Influenza BMI Protein.
￿
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FIGURE 2.
￿
Effect ofamino acid substitutions in the
ERKRRmotifon immunoreactivity ofgroup 11 sera .
(a) Immunoreaction of group II sera with recom-
binantMS2polymerase fusion proteins containing
domain A-derived sequences (corresponding to pep-
tide R6 ; see Fig. 1) with single amino acid substitu-
tions as indicated . (b)Immunoblot ofgroup 11 serum
UB (diluted 1/400) with bacterial protein extracts
from E . coli expressing the various fusion proteins
(lanenumberscorrespond to numbers in a). Amino
acid substitutions within theERKRRmotifabolished
immunoreaction of the serum (lanes 4-7), whereas
exchanges in the flanking regions did not (lanes 2,
3, and 8).TheMS2polymerase protein (14kD)was
not immunostained (lane 9) . M, molecular weight
markers. (c) Region of a Coomassie-stained SDS-
polyacrylamide gel with the recombinant p68domain
A proteins to demonstrate that similaramounts of
fusion proteins have been used for immunoblotting .
investigate if human autoantibodies recognize the ERKRR motif also in the viral
sequence context, anti-ERKRR autoimmune sera were incubated on immunoblots
with proteins of influenza B virus separated by SDS-PAGE. As shown for a repre-
sentative example (Fig. 3 a, lane 1), the sera reacted with the Ml protein (27 kD),
as well as with a variety ofother viral proteins, indicating aprevious viral infection
or vaccination . Preincubation of the sera with peptide R12 (ERKRR) resulted in
reduced staining of the matrix protein (Fig. 3 a, lane 2), suggesting that at least
part of the anti-Ml response was due to anti-ERKRR antibodies . The specificity
of the inhibition was demonstrated by preincubation ofa control pentapeptide R4
(REKIE), which did not reduce the staining intensity (Fig. 3 a, lane 3) . To further
prove crossreactivity, anti-ERKRR autoantibodies were affinity purified fromatrun-
catedMS2 domainA fusion protein (labeled 1 in Fig . 2 a) and incubated on immu-
noblots with influenza B virus proteins . Strong staining was observed solely with
theMl protein (Fig. 3 a, lane 4), and this was drastically reduced upon preincuba-
tion of the purified antibodies with peptide R12 (Fig. 3 a, lane 5) but not with con-
trol peptide R4 (Fig . 3 a, lane 6) . A reaction of affinity-purified antibodies withM1
protein of influenzaA viruses (which do not have the ERKRRmotif) was not ob-
served (Fig . 3 a, lane 7) .
In a different set of experiments, patient antibodies were affinity purified from
influenza BMl protein . These antibodies reacted strongly with the domainA pep-
tide R1 in ELISA (Fig . 4, column 1, B), whereas antibodies purified from influenza
AMl protein did not (Fig. 4, column 1, A) . Again, anti-ERKRR antibodies were824
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FIGURE 3 .
￿
Crossreaction of anti-ERKRR autoanti-
bodies with influenzaB Ml matrix protein. (a)Immu-
noblots of influenzaB (lanes 1-6) and influenzaA pro-
teins (lane 7). (Lanes 1-3) Incubation ofERKRRpositive
serum from patientUG(dilution 1/400) ; lane 1, without
preincubation ofpeptide; lane 2, with preincubation of
ERKRR peptideR12 ; lane 3, with preincubation ofcon-
trol peptide R4 (REKIE). (Lanes 4-7) Incubation of
anti-ERKRR autoantibodies from patient UG affinity
purified from truncatedMS2domainAfusion protein ;
lanes 4 and 7, without preincubation of peptide; lane
5, with preincubation ofpeptideR12; lane 6, with prein-
cubation of control peptide R4 . (b) Coomassie
Blue-stained SDS gel with influenza B (10 14g protein ;
lane 1) and influenza A virus proteins (10 wg protein ;
lane 2) used for immunoblotting ; M, molecular weight
markers.
responsible for crossreaction, since preincubation with theERKRR peptide reduced
the signal by >70% (Fig. 4, column 2, B) .
Anti-ERKRR antibodies were not found in >50 healthy individuals tested, nor
in anti-p68 - sera from patients with various rheumatic diseases and high titers of
autoantibodies to other antigens (e.g ., Sm, Ro, La, centromere, topoisomerase I,
PM-Scl, histones, dsDNA, fibrillarin, Jo-1 ; data not shown) . This demonstrates the
specificity of the immune reaction and rules out binding of antibodies unrelated
to anti-p68 to the ERKRR epitope .
Taken together, the-° data establish that a subset of human anti-p68 autoanti-
bodies recognize an epitopeshared by the p68 autoantigenand theinfluenzaB virus
M1 matrix protein, and that the different sequence context does not interfere with
crossreactivity of the antibodies .
Immunoreactiaity ofMouseMono- andPolyclonalAntip68Antibodies.
￿
We investigated
if anti-ERKRR antibodies can be induced experimentally by immunizing nonau-
toimmune mice either withdomainApeptide R1 or MS2 domainA fusion protein .GULDNER ET AL .
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FIGURE 4.
￿
Crossreaction of human anti-ERKRR antibodies (from
MCTD patient JS) affinity purified from influenza B Ml protein with
p68-derived peptide Rl in ELISA . Antibodies purified from influenza
B virus Ml protein (bars labeled B) gave a strong signal with peptide
Rl (1), which was markedly reduced afterpreincubation with theERKRR
pentapeptide R12 (2), but not with peptide R4 (3) . In a control experi-
ment, antibodies purified from influenza A virus Ml protein (bars la-
beled A) were not reactive with the Rl peptide.
Each of the 10 animals immunized developed high titers of antibodies to domain
A as revealed byELISA with peptide RI and immunoblotting withdomainAfusion
protein (data not shown) . ERKRRspecific antibodies, however, were not detectable
either by competitive inhibition ELISA, as described in Fig. 1, or in ELISA with
asolid-phase coupled peptide derived from the influenza BMl protein (amino acid
position 66-85: NH2-FLKPKDQERKRRFITEPLSG-COOH; data not shown) . It
is possible that induction ofanti-ERKRR antibodies depends on a specific confor-
mation not adopted by the synthetic peptide (for a general discussion, seereference
28) and/or on genetically determined factors involved in immune recognition .
Three anti-p68 mAbs from autoimmune mice (29 ; andD. G. Williams, personal
communication) or normal mice immunized with snRNPs (30) failed to show any
immunoreactivity withdomain A-spanning peptideRI (datanot shown), indicating
the absence of antibodies with specificity towards the ERKRR motif.
Discussion
In this study, asequence motifoffiveamino acids was identified as an autoepitope
recognized by a subset of anti-p68 autoantibodies from (UI)RNP-positive patients'
sera. The same motif was found on the influenza B virus M1 matrix protein and
was recognized by human anti-p68 autoantibodies also in the viral sequence con-
text . Theoccurrence inautoimmune sera of antibodies reactive with the shared epi-
tope maybe causally relatedby representing an example of molecularmimicry . This
would implicate that influenzaBviruses, whicharehighly prevalenthuman pathogens,
could act as trigger for development of autoantibodies to p68 . Recently, a similar
hypothesis has been raised for retroviruses (14, 31) based on the identification ofa
crossreactive epitope on the human p68-autoantigen and p30gag protein of non-
human retroviruses . Theexistence ofacommon epitope ofp68 andamurine retrovirus
has been confirmed in an independent study (data not shown) . There is, however,
so far no evidence for the existence of a protein of a human retrovirus exhibiting
such an epitope .
Several features ofthe influenza viruses render them particularly attractive candi-
dates for contributing to autoimmune processes . First, they are known to interact
with lymphocytes (32), whichmaylead to partialbreakdown ofself-tolerance ; second,826
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they can cause polyclonal B cell activation (33), which is considered important for
autoantibody formation (34); third, influenza viruses impair function of phagocytes
(35), which maybe followed by delayed clearanceofself-antigens (including snRNP
particles) released from necrotic cells; fourth, p68 as an RNA-binding protein (36)
may interact with influenza virus RNA and thus be secreted in virus-encapsulated
form, rendering the extracellular p68 a possible target for B cells; and fifth, a high
percentage of influenza virus-infected patients have been described to develop au-
toantibodies (7).
Based on the identification of multiple autoepitopes recognized by anti-p68 sera,
the role of the p68 protein as an immunogen at some stage of the autoimmune pro-
cess has been suggested (17). In addition to possibly initiating autoimmunity by mo-
lecular mimicry, influenza B might promote such an antigen-driven process by re-
lease of snRNP as a consequence of virus-induced cell lysis.
It is generally accepted that multiple factors areinvolved in autoimmunity: genetic
predisposition, immune deficiency, andhormonal, environmental, and other influences
(37). Therefore, not all individuals infected with influenza B would be expected to
develop anti-p68 autoantibodies.
Only a subset of anti-p68 autoimmune sera (13/103) was found to contain anti-
ERKRR antibodies. It is, however, conceivable that in some cases crossreacting anti-
ERKRR antibodies are present during viral infection only and may later disappear
becauseofviral antigenelimination andlowimmunogenicity ofthe shared self-epitope.
Nevertheless, the autoimmunization process once startedby thecrossreacting anti-
body may continue in an antigen-driven fashion. Consistent with this speculation
is the finding of high titers of anti-ERKRR antibodies in early sera of two anti-p68
autoimmune patients that dropped to undetectable levels during progression of the
rheumatic disease. In the same patients, the antibody titers to other p68 epitopes
remained unchanged (data not shown).
To further investigate the potential involvement of influenza B viruses in autoim-
munity, it will be interesting to examine whether ERKRRspecific antibodies com-
monly occurin patients infected or vaccinated with influenzaBviruses. If, as hypothe-
sized, initiation of the autoimmune response by molecular mimicry is occurring,
vaccinationwith inactivated virus and notonly infection could lead to autoimmune
phenomena, provided other predisposing factors are present. Direct experimental
testing of the possible role of influenza B viruses as initiators for the formation of
anti-p68, and eventually ofotheranti-(Ul)snRNP autoantibodies, can be performed.
In case of presence of the appropriate exogenous and endogenous parameters, infec-
tion of animals with influenza B viruses may provide experimental evidence for its
possible trigger function in autoimmunity to snRNP
Summary
Autoantibodies from patients with systemic rheumatic diseases were used to map
antigenic siteson the68-kD autoantigen(p68) associated with (U1)RNA-containing
small nuclear ribonucleoprotein (snRNP) particles. With truncated recombinant
fusion proteins andsynthetic peptides, a subset of anti-p68 autoantibodies wasfound
to recognize the amino acid sequence motif Glu-Arg-Lys-Arg-Arg (ERKRR). To
investigate the possible involvement of epitopes shared by microbial antigens and
host self-components in initiation ofautoimmunity (molecular mimicry), a sequencedata bank was screened for proteins containing an amino acid motif identical or
related to ERKRR. The identical motif was found on the M1 matrix protein of
influenza B viruses, and affinity-purified human anti-ERKRR autoantibodies rec-
ognized this epitope also in the viral amino acid sequence context. The common
epitope recognized by human autoantibodies suggests that influenza B virus infec-
tion may play a role in initiation of the anti-p68 and anti-(Ul)RNP autoimmune
response.
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